Debby Wensink

Debby Wensink

Auto-generated profile, based on publicly available information

Debby Wensink

Porphyria Expertcenter Rotterdam, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC Erasmus University Medical Center Rotterdam Rotterdam the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
DWDebby Wensink
Debby Wensink
MWMargreet Wagenmakers
Margreet Wagenmakers
JLJanneke Langendonk
Janneke Langendonk
In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain aft...

1 April 2022 in Digestive and Liver Disease
Verified
Journal Article
Open access
DWDebby Wensink
Debby Wensink
.C. Coenen
. Coenen
JWJ.H. Paul Wilson
J.H. Paul Wilson
MWMargreet Wagenmakers
Margreet Wagenmakers
JLJanneke Langendonk
Janneke Langendonk
In erythropoietic protoporphyria (EPP), which presents with severe painful phototoxicity, progressive deposition of protoporphyrins in hepatocytes and bile canaliculi may result in liver disease. Clinically EPP related liver disease ranges from mildly elevated liver enzymes to cirrhosis and acute cholestatic hepatic failure. The prevalence of liver disease in EPP, and factors predicting the risk of developing liver disease, have not been defined in a large series of unselected EPP patients. To determine the prevalence of liver disease in EPP-patients. A single-center prospective unselected cohort study of 114 adult EPP patients, who underwent routine laboratory testing, abdominal ultrasonography and transient elastography to assess the presence of steatosis (controlled attenuation parameter,dB/m) and liver stiffness (kPa). 114 adult EPP patients were included. Elevated liver enzymes were found in 6.2% of the patients. Liver steatosis was detected in 29.0%, and significant fibrosis as assessed with liver stiffness measurements was present in 9.6% of patients. BMI positively predicted CAP-values (p = 0.026); and protoporphyrin IX levels (p = 0.043) positively predicted liver stiffness. This study demonstrates a prevalence of hepatic steatosis and fibrosis in adult EPP-patients comparable to that found in the general population. Protoporphyrin IX levels correlate with increased liver stiffness in EPP.

28 December 2022 in The Journal of Dermatology
Verified
Journal Article
Open access
DWDebby Wensink
Debby Wensink
MWMargreet Wagenmakers
Margreet Wagenmakers
JWJ. H. Paul Wilson
J. H. Paul Wilson
JLJanneke Langendonk
Janneke Langendonk
Erythropoietic protoporphyria (EPP) patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. However, there is limited information on the psychosocial aspects of EPP. To investigate the clinical features and social aspects of living with EPP, before and during afamelanotide treatment in the Netherlands. A single‐center prospective longitudinal study of adult patients with EPP attending the Erasmus MC Rotterdam. Patients completed questionnaires, comprising demographic, clinical and social details, including two generic (DS‐14 and SF‐36) and a disease specific (EPP‐QoL) QoL questionnaires. 121 adult EPP patients were included. The educational level of EPP patients seemed higher compared to the Dutch population (36% vs. 30% high‐education, 42% vs. 37% middle‐education). At baseline 5% of the EPP patients were unemployed, none were unemployed during afamelanotide treatment. Full‐ and part‐time employment rate increased from 59.5% to 69.9% on afamelanotide treatment (p > 0.05). EPP‐QoL improved from 44% to 75% on afamelanotide treatment (p < 0.001). Type‐D personality was present in 27.4% of patients; their social inhibition scores improved significantly on afamelanotide treatment (p = 0.019). EPP patients scored low on the social functioning domain (SF‐36) compared to the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4; respectively), and improved during afamelanotide treatment (84.3 ± 20.9, p = 0.001). EPP has a significant negative impact on social aspects, with less employment despite a higher education level. Afamelanotide treatment improves quality of life, social functioning and possibly employment rate. It is important to recognize the impact of EPP on social life, although, more research is needed.

2 January 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
DWDebby Wensink
Debby Wensink
MWMargreet Wagenmakers
Margreet Wagenmakers
HQHongchao Qi
Hongchao Qi
JWJ.H. Paul Wilson
J.H. Paul Wilson
JLJanneke Langendonk
Janneke Langendonk